"a Phase III company with a solid pipeline and $500 million NEO with Amgen " on the verge of EMA approval (months not years away) is hardly worth less than a market cap of 3 billion, let alone 300 million.
Plainly speaking, the current Advaxis market cap is one of the most absurdly low valuations on Nasdaq today.